<DOC>
	<DOCNO>NCT02721966</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy safety secukinumab 150 mg 300 mg management axial manifestation PsA patient fail respond least 2 non-steroidal anti-inflammatory drug ( NSAIDs ) 4-week period , accord assessment spondyloarthritis international society ( ASAS ) recommendation treatment axial spondyloarthritis ( AxSpA ) .</brief_summary>
	<brief_title>Study Efficacy Safety Secukinumab Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>Written informed consent must obtain assessment perform Diagnosis psoriatic arthritis classify Classification criterion psoriatic arthritis ( CASPAR ) criterion Active spinal disease define Bath ankylose spondylitis disease activity index ( BASDAI ) score ≥ 4 Spinal Pain visual analog scale ( VAS ) ≥ 40 ( VAS 100 scale ) Inadequate Response least 2 nonsteroidal antiinflammatory drug 4 week period History exposure IL17 IL23 inhibitor biologic drug History exposure previous biologic disease modify antirheumatic drug ( DMARDs ) ( Tumor necrosis factor ( TNF ) blocker Ustekinumab ) Current treatment disease modify antirheumatic drug ( DMARDs ) Methotrexate Subjects take high potency opioid analgesic ( e.g . methadone , hydromorphone , morphine ) Chest Xray chest magnetic resonance imaging ( MRI ) evidence ongoing infectious malignant process , obtain within 3 month prior screen evaluate qualified physician Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Assessment spondyloarthritis international society ( ASAS )</keyword>
	<keyword>ASAS</keyword>
	<keyword>axial</keyword>
	<keyword>Psoriatic Arthritis ( PsA )</keyword>
	<keyword>PsA</keyword>
	<keyword>Magnetic resonance imaging ( MRI )</keyword>
	<keyword>MRI</keyword>
</DOC>